Story 2

Industry Insights – August 2026

Stay in tune with the growing changes in drug access and regulatory transparency, including rising insurance denials for brand-name medications and FDA updates around rejection letters and advisory committees. Read on for a closer look at developments shaping the biopharma industry. Source: PharmaVoice Insurance denials for brand-name prescription drugs have Read more

By Jason Shaneyfelt, ago